(ISRG) Intuitive Surgical - Overview
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 149.145m USD | Total Return: -19.3% in 12m
Avg Turnover: 931M
EPS Trend: 99.9%
Qual. Beats: 4
Rev. Trend: 99.6%
Qual. Beats: 7
Warnings
Below Avwap Earnings
Tailwinds
Confidence
Intuitive Surgical, Inc. (ISRG) specializes in the development and manufacturing of robotic-assisted technologies designed for minimally invasive medical procedures. Its primary product, the da Vinci Surgical System, facilitates complex surgeries through small incisions, while the Ion endoluminal system focuses on diagnostic lung biopsies. The company’s business model relies on a razor-and-blade strategy, generating recurring revenue through the sale of proprietary instruments, accessories, and long-term service contracts required to maintain its installed base of capital equipment.
The healthcare equipment sector is characterized by high barriers to entry due to stringent regulatory requirements and the significant research and development costs associated with surgical robotics. Intuitive Surgical maintains its market position through an integrated ecosystem that includes physician training, technical support, and data-driven performance analytics for hospitals. For a deeper look into the companys valuation metrics, consider reviewing the detailed financial breakdowns on ValueRay.
Headquartered in Sunnyvale, California, the company operates via a direct sales model to distribute its technology to global healthcare providers. Its product suite extends beyond hardware to include digital capabilities and proactive system monitoring, ensuring operational uptime for its surgical and diagnostic platforms.
- Growth in procedure volumes drives recurring revenue from instruments and accessories
- Adoption of da Vinci 5 system accelerates capital equipment replacement cycles
- Expansion into diagnostic lung biopsy markets via Ion system penetration
- International procedure growth offsets domestic healthcare budget constraints and competition
- Regulatory clearance timelines for new surgical indications impact market expansion velocity
| Net Income: 2.98b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 5.01 > 1.0 |
| NWC/Revenue: 90.80% < 20% (prev 70.22%; Δ 20.58% < -1%) |
| CFO/TA 0.17 > 3% & CFO 3.36b > Net Income 2.98b |
| Net Debt (-4.16b) to EBITDA (3.96b): -1.05 < 3 |
| Current Ratio: 6.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (359.8m) vs 12m ago -1.32% < -2% |
| Gross Margin: 66.29% > 18% (prev 0.67%; Δ 6.56k% > 0.5%) |
| Asset Turnover: 53.81% > 50% (prev 45.34%; Δ 8.47% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.48 (Total Current Assets 11.5b - Total Current Liabilities 1.91b) / Total Assets 20.1b |
| B: 0.32 (Retained Earnings 6.40b / Total Assets 20.1b) |
| C: 0.16 (EBIT TTM 3.22b / Avg Total Assets 19.7b) |
| D: 2.55 (Book Value of Equity 6.41b / Total Liabilities 2.51b) |
| Altman-Z'' = 7.95 = AAA |
| DSRI: 1.04 (Receivables 1.71b/1.35b, Revenue 10.6b/8.71b) |
| GMI: 1.01 (GM 66.29% / 67.09%) |
| AQI: 0.44 (AQ_t 0.16 / AQ_t-1 0.35) |
| SGI: 1.21 (Revenue 10.6b / 8.71b) |
| TATA: -0.02 (NI 2.98b - CFO 3.36b) / TA 20.1b) |
| Beneish M = -3.17 (Cap -4..+1) = AA |
As of May 23, 2026, the stock is trading at USD 439.80 with a total of 1,847,601 shares traded.
Over the past week, the price has changed by +4.03%,
over one month by -9.41%,
over three months by -10.97% and
over the past year by -19.27%.
Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.
- StrongBuy: 14
- Buy: 8
- Hold: 10
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 577 | 31.2% |
P/E Forward = 43.4783
P/S = 14.0941
P/B = 9.1216
P/EG = 2.3633
Revenue TTM = 10.6b USD
EBIT TTM = 3.22b USD
EBITDA TTM = 3.96b USD
Long Term Debt = unknown (none)
Short Term Debt = 39.0m USD (from shortTermDebt, last fiscal year)
Debt = 389.8m USD (from shortLongTermDebtTotal, last fiscal year) + Leases 87.0m
Net Debt = -4.16b USD (calculated: Debt 389.8m - CCE 4.55b)
Enterprise Value = 145b USD (149b + Debt 389.8m - CCE 4.55b)
Interest Coverage Ratio = unknown (Ebit TTM 3.22b / Interest Expense TTM 0.0)
EV/FCF = 51.15x (Enterprise Value 145b / FCF TTM 2.83b)
FCF Yield = 1.95% (FCF TTM 2.83b / Enterprise Value 145b)
FCF Margin = 26.78% (FCF TTM 2.83b / Revenue TTM 10.6b)
Net Margin = 28.15% (Net Income TTM 2.98b / Revenue TTM 10.6b)
Gross Margin = 66.29% ((Revenue TTM 10.6b - Cost of Revenue TTM 3.57b) / Revenue TTM)
Gross Margin QoQ = 66.06% (prev 66.44%)
Tobins Q-Ratio = 7.21 (Enterprise Value 145b / Total Assets 20.1b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 389.8m)
Taxrate = 12.17% (114.4m / 940.4m)
NOPAT = 2.83b (EBIT 3.22b * (1 - 12.17%))
Current Ratio = 6.03 (Total Current Assets 11.5b / Total Current Liabilities 1.91b)
Debt / Equity = 0.02 (Debt 389.8m / totalStockholderEquity, last quarter 17.5b)
Debt / EBITDA = -1.05 (Net Debt -4.16b / EBITDA 3.96b)
Debt / FCF = -1.47 (Net Debt -4.16b / FCF TTM 2.83b)
Total Stockholder Equity = 17.5b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.15% (Net Income 2.98b / Total Assets 20.1b)
RoE = 17.01% (Net Income TTM 2.98b / Total Stockholder Equity 17.5b)
RoCE = 17.71% (EBIT 3.22b / Capital Employed (Total Assets 20.1b - Current Liab 1.91b))
RoIC = 15.52% (NOPAT 2.83b / Invested Capital 18.2b)
WACC = 8.96% (E(149b)/V(150b) * Re(8.98%) + D(389.8m)/V(150b) * Rd(0.0%) * (1-Tc(0.12)))
Discount Rate = 8.98% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 11.11 | Cagr: 0.20%
[DCF] Terminal Value 76.03% ; FCFF base≈2.40b ; Y1≈2.75b ; Y5≈4.05b
[DCF] Fair Price = 167.1 (EV 55.0b - Net Debt -4.16b = Equity 59.2b / Shares 354.2m; r=8.96% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.90 | EPS CAGR: 26.28% | SUE: 2.92 | # QB: 4
Revenue Correlation: 99.58 | Revenue CAGR: 18.67% | SUE: 2.86 | # QB: 7
EPS current Quarter (2026-06-30): EPS=2.50 | Chg30d=+1.04% | Revisions=+36% | Analysts=25
EPS next Quarter (2026-09-30): EPS=2.58 | Chg30d=+0.08% | Revisions=-8% | Analysts=25
EPS current Year (2026-12-31): EPS=10.41 | Chg30d=+3.95% | Revisions=+80% | GrowthEPS=+16.6% | GrowthRev=+16.3%
EPS next Year (2027-12-31): EPS=11.79 | Chg30d=+3.16% | Revisions=+87% | GrowthEPS=+13.2% | GrowthRev=+13.3%
[Analyst] Revisions Ratio: +87%